parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in proximal tubule cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 5887

SLC12A7 in microglia, braak-0.58 (p 0.102) → -0.05 (p 0.894)receipt 5895
SLC12A7 in dopamine neurons, braak-0.16 (p 0.680) → -0.64 (p 0.063)receipt 5896

receipt 5896: SLC12A7 in dopamine neurons, braak

power: full sample -0.36 (p 0.137, n 18), 95% CI -0.71 to +0.12. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.36 (p 0.137, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.109, n 18). could be the mix.
skeptic: leave-one-out range -0.54 to -0.29, sign flips 0; without severely affected donors -0.36 (p 0.137, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC12A7 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5895: SLC12A7 in microglia, braak

power: full sample -0.33 (p 0.182, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.28 (p 0.258, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.29 (p 0.250, n 18). could be the mix.
skeptic: leave-one-out range -0.43 to -0.23, sign flips 0; without severely affected donors -0.33 (p 0.182, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC12A7 in microglia.

case closed: nothing better to follow up.

loading the receipts